OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -25.36 Million CAD | -66.78% |
| 2022 | -15.2 Million CAD | 64.57% |
| 2021 | -42.92 Million CAD | 47.06% |
| 2020 | -122.66 Million CAD | -690.1% |
| 2019 | 12.69 Million CAD | -65.6% |
| 2018 | 41.39 Million CAD | 515.39% |
| 2017 | -9.61 Million CAD | -573.41% |
| 2016 | 2.03 Million CAD | 372.96% |
| 2015 | -746.64 Thousand CAD | -797.03% |
| 2014 | 106.76 Thousand CAD | 128.45% |
| 2013 | -375.24 Thousand CAD | -167.72% |
| 2012 | -140.16 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -13.02 Million CAD | 61.61% |
| 2024 Q2 | -21.24 Million CAD | -83.51% |
| 2024 Q3 | -15.85 Million CAD | 124.71% |
| 2023 Q3 | -21.65 Million CAD | -415.18% |
| 2023 FY | - CAD | -480.12% |
| 2023 Q1 | 10.45 Million CAD | 13853.95% |
| 2023 Q2 | -4.2 Million CAD | -140.21% |
| 2023 Q4 | -33.93 Million CAD | -56.74% |
| 2022 Q2 | -1.41 Million CAD | 81.85% |
| 2022 Q3 | -5.91 Million CAD | -317.87% |
| 2022 Q4 | -76 Thousand CAD | 98.72% |
| 2022 FY | - CAD | 64.57% |
| 2022 Q1 | -7.8 Million CAD | -277.72% |
| 2021 Q4 | 4.38 Million CAD | 203.05% |
| 2021 Q1 | -21.35 Million CAD | 46.06% |
| 2021 Q2 | -21.7 Million CAD | -1.62% |
| 2021 FY | - CAD | 47.06% |
| 2021 Q3 | -4.25 Million CAD | 80.37% |
| 2020 FY | - CAD | -690.1% |
| 2020 Q1 | 3.25 Million CAD | 113.45% |
| 2020 Q2 | -5000.00 CAD | -100.15% |
| 2020 Q3 | -53.77 Million CAD | -1075380.0% |
| 2020 Q4 | -39.58 Million CAD | 26.38% |
| 2019 FY | - CAD | -65.6% |
| 2019 Q2 | -473 Thousand CAD | -100.99% |
| 2019 Q4 | -24.21 Million CAD | -154.76% |
| 2019 Q3 | -9.5 Million CAD | -1909.51% |
| 2019 Q1 | 47.93 Million CAD | 62.49% |
| 2018 Q3 | 8.56 Million CAD | 201.26% |
| 2018 Q4 | 29.49 Million CAD | 244.31% |
| 2018 FY | - CAD | 515.39% |
| 2018 Q2 | 2.84 Million CAD | 394.56% |
| 2018 Q1 | -965.45 Thousand CAD | 39.38% |
| 2017 FY | - CAD | -573.41% |
| 2017 Q4 | -1.59 Million CAD | 23.53% |
| 2017 Q1 | -416.19 Thousand CAD | -143.87% |
| 2017 Q2 | -5.52 Million CAD | -1227.45% |
| 2017 Q3 | -2.08 Million CAD | 62.31% |
| 2016 Q4 | 948.62 Thousand CAD | 36.35% |
| 2016 FY | - CAD | 372.96% |
| 2016 Q3 | 695.71 Thousand CAD | 87.96% |
| 2016 Q2 | 370.13 Thousand CAD | 2109.79% |
| 2016 Q1 | 16.75 Thousand CAD | -92.32% |
| 2015 Q2 | -520.88 Thousand CAD | 30.47% |
| 2015 Q1 | -749.2 Thousand CAD | -298.75% |
| 2015 FY | - CAD | -797.03% |
| 2015 Q4 | 218.12 Thousand CAD | -28.56% |
| 2015 Q3 | 305.31 Thousand CAD | 158.61% |
| 2014 Q3 | -25.18 Thousand CAD | -60.49% |
| 2014 Q2 | -15.69 Thousand CAD | -109.79% |
| 2014 Q1 | 160.31 Thousand CAD | 1365.0% |
| 2014 Q4 | -187.88 Thousand CAD | -646.03% |
| 2014 FY | - CAD | 128.45% |
| 2013 FY | - CAD | -167.72% |
| 2013 Q3 | -2962.00 CAD | 94.95% |
| 2013 Q1 | -252.8 Thousand CAD | -315.97% |
| 2013 Q4 | -12.67 Thousand CAD | -327.85% |
| 2013 Q2 | -58.7 Thousand CAD | 76.78% |
| 2012 Q2 | -81.03 Thousand CAD | -1168.18% |
| 2012 Q3 | -43.44 Thousand CAD | 46.39% |
| 2012 Q4 | -60.77 Thousand CAD | -39.9% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | -6390.00 CAD | 31.26% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | -9296.00 CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Theratechnologies Inc. | -10.31 Million USD | -145.959% |
| Harrow Health, Inc. | 9.72 Million USD | 360.879% |
| Dynavax Technologies Corporation | 9.66 Million USD | 362.417% |
| Biofrontera Inc. | -18.45 Million USD | -37.459% |
| Cronos Group Inc. | -72.14 Million USD | 64.843% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -460.558% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 97.257% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 29.701% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 196.57% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -3468.296% |
| Radius Health, Inc. | 38.31 Million USD | 166.21% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -688.948% |
| DURECT Corporation | -24.68 Million USD | -2.76% |
| ProPhase Labs, Inc. | -14.82 Million USD | -71.075% |
| Safety Shot Inc | -12.18 Million USD | -108.165% |
| Phibro Animal Health Corporation | 84.6 Million USD | 129.98% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -978.908% |
| Alvotech | -484.86 Million USD | 94.769% |
| Assertio Holdings, Inc. | -222.44 Million USD | 88.597% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 125.814% |
| Rockwell Medical, Inc. | -4.69 Million USD | -440.376% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -563.244% |
| Procaps Group S.A. | 104.02 Million USD | 124.383% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 84.032% |
| SCYNEXIS, Inc. | 73.47 Million USD | 134.52% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -2406.446% |
| Viatris Inc. | 3.51 Billion USD | 100.721% |
| OptiNose, Inc. | -15.55 Million USD | -63.089% |
| SIGA Technologies, Inc. | 84.15 Million USD | 130.139% |
| Tilray Brands, Inc. | -72.84 Million USD | 65.178% |
| PetIQ, Inc. | 81.48 Million USD | 131.128% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -563.244% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 106.096% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -546.684% |
| Alimera Sciences, Inc. | 7.27 Million USD | 448.615% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 108.227% |
| Silver Spike Investment Corp. | 7.34 Million USD | 445.57% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -535.617% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 170.398% |
| Journey Medical Corporation | 1.92 Million USD | 1420.418% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -502.232% |
| Alpha Teknova, Inc. | -25.53 Million USD | 0.68% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -50.948% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 3223.797% |
| PainReform Ltd. | -9.56 Million USD | -165.077% |
| Cosmos Health Inc. | -17.06 Million USD | -48.667% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 82.991% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -201.931% |
| Embecta Corp. | 245.4 Million USD | 110.336% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -601.156% |
| Talphera, Inc. | -9.84 Million USD | -157.724% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 115.571% |
| Incannex Healthcare Limited | -18.5 Million USD | -37.08% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -26.631% |
| Shineco, Inc. | -26.55 Million USD | 4.476% |
| Procaps Group, S.A. | 104.02 Million USD | 124.383% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 123.203% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 2245.959% |
| Lantheus Holdings, Inc. | 491 Million USD | 105.166% |
| Alvotech | -484.86 Million USD | 94.769% |
| Hempacco Co., Inc. | -12.77 Million USD | -98.581% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 132.728% |
| Bright Green Corporation | - USD | Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 83.102% |
| Kamada Ltd. | 21.53 Million USD | 217.792% |
| Indivior PLC | 66 Million USD | 138.432% |
| Evoke Pharma, Inc. | -7.29 Million USD | -247.836% |
| Flora Growth Corp. | -45.87 Million USD | 44.702% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -26.631% |
| Evolus, Inc. | -41.81 Million USD | 39.332% |
| HUTCHMED (China) Limited | 25.52 Million USD | 199.362% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 110.505% |
| Akanda Corp. | -27.73 Million USD | 8.547% |